Navigation Links
Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Apr 10, 2007 - Valeant Pharmaceuticals International (NYSE:VRX) announced today the publication of Phase 2 data for retigabine, a first-in-class neuronal potassium channel opener, in Neurology, a leading independent, scientific journal. The authors concluded that retigabine was efficacious with a demonstrated reduction in monthly seizure rates in this study. Two pivotal Phase 3 trials (RESTORE1 and RESTORE2) are currently underway to further investigate the efficacy and safety of retigabine as an adjunctive treatment for partial-onset seizures in patients with refractory epilepsy.

"There is a clear need for the development of antiepileptic drugs with new mechanisms of action to improve the management of patients whose epilepsy is not controlled by current medications," said Phase 2 study investigator and lead author Roger J. Porter, M.D., University of Pennsylvania. "This new molecule clearly acts by way of a different neuronal mechanism and if approved, would meet a market need. The Phase 2 data published in Neurology indicate that retigabine was efficacious for these hard-to-treat partial seizures in this study."

"We are pleased that these important findings have been published in Neurology," said Wesley P. Wheeler, president, North America and research and development. "Valeant is committed to developing innovative drugs for neurological disorders. We believe that potassium-channel openers with their unique mechanisms of action will advance the treatment of epilepsy."

In the study, investigators found that during the 8-week dose-escalation and 8-week maintenance periods, the addition of retigabine 600, 900 or 1,200 mg per day significantly reduced median monthly seizure frequency compared to baseline by 23, 29 and 35 percent, respectively. The reductions in the 900 and 1,200 mg groups were significantly greater than in the placebo group (13 percent vs. base
'"/>




Page: 1 2 3

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:12/24/2014)... -- The International Trade Commission (ITC) issued its final decision in ... a notice issued on December 23, the ITC ruled in ... humidifier was invalid. BMC President, James Xu ... excited with the ITC,s decision in this case. This victory ... the very beginning on the key patents in the case. ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, ... PTN), a biopharmaceutical company developing targeted, receptor-specific peptide ... unmet medical need and commercial potential, today announced ... of 2,050,000 shares of its common stock and ... its common stock.  Funds under the management of ...
(Date:12/24/2014)... PHILADELPHIA , Dec. 23, 2014 ... a medical device company focused on skin permeation, ... that Scott W. Hollander has been ... Mr. Hollander has more than 20 years of ... equipment industries, and most recently served as Vice ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3
... 17, 2011 Damage to the spine can happen for ... car accident, wear and tear from old age, or blunt ... past have had to deal with back braces, reduced mobility, ... Seyed M. Rezaian,s patented Spinal Fixator, patients are able to ...
... Unilife Corporation ("Unilife" or the "Company") (NASDAQ: ... Deputy Secretary of the U.S. Department of Agriculture, for a ... at its facility in York, Pennsylvania. The White ... direction of President Obama. The Winning the Future Roundtables ...
Cached Medicine Technology:Dr. Seyed M. Rezaian's Spinal Fixator a Revolutionary Invention for Healing Injuries of the Thoracolumbar Spine 2Unilife Hosts White House Business Council Meeting 2Unilife Hosts White House Business Council Meeting 3
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – ... current treatment landscape, unmet needs, current pipeline and commercial ... anti-cancer drug which is typically used for treating colorectal ... for treating gastric cancer and pancreatic cancer. TS-1 is ... was first approved in 1999 in Japan for the ...
(Date:12/25/2014)... “Every three months the trends for ... evening dress will be one of the hottest styles in ... says. Today, the company releases 26 A-line sweetheart evening dresses, ... off. , “We are trying our best to help ... latest designs. Along with affordable prices, we provide discounted delivery ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, Dylan ... dresses, has excitedly released its collection of discounted prom ... to Percy, a senior spokesman of the company, the ... of this promotion is to expand the UK market. ... in several different colors, lengths, and styles: A-line strapless, ...
(Date:12/25/2014)... December 25, 2014 Recently, BellasDress ... on all its wedding dresses. BellasDress has chosen their ... for gift choices for the holiday season. , ... pick suitable wedding gowns here at discount prices. The ... experience at its website. , “All our ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2
... for future treatments, researchers say , MONDAY, March 22 ... with an increased risk for lung cancer in people ... analyzed DNA from more than 1,000 people with lung ... found strong evidence that two variations in a gene ...
... , ... medical marketing newsletter Healthcare Success Marketing Advisor has just surpassed the 10,000 subscriber milestone. ... (PRWEB) March ... Healthcare Success Marketing Advisor has just surpassed over 10,000 subscribers., , ,Written and ...
... Today, the U.S. Agency for International Development (USAID) ... US$12.7 million in their global partnership, the Water ... eight new multi-year programs throughout sub-Saharan Africa in Angola ... Mozambique , Senegal , South Africa , ...
... , March 22 Actress and philanthropist Holly Robinson Peete has partnered with ... example" by making smart food choices their children can emulate. MHAIA,s goal is to help reduce the ... ... ...
... ... trial, funded by the Mesothelioma Applied Research Foundation, publishes successful results for mesothelioma treatment. ... (PRWEB) ... trial to be well-tolerated and capable of inducing an immunological response against mesothelioma cells ...
... ... Hawaii , is unveiling a new, interactive website geared toward educating web visitors about state-of-the-art ... ... obesity, weighing 80 pounds or more over the average for their size and body type. ...
Cached Medicine News:Health News:Medical Marketing Newsletter Reaches 10,000 Subscribers 2Health News:The Coca-Cola Company and USAID Expand Global Water Partnership 2Health News:The Coca-Cola Company and USAID Expand Global Water Partnership 3Health News:The Coca-Cola Company and USAID Expand Global Water Partnership 4Health News:The Coca-Cola Company and USAID Expand Global Water Partnership 5Health News:The Coca-Cola Company and USAID Expand Global Water Partnership 6Health News:Avocados from Mexico Encourages Parents to Model Good Eating Habits 2Health News:Avocados from Mexico Encourages Parents to Model Good Eating Habits 3Health News:Avocados from Mexico Encourages Parents to Model Good Eating Habits 4Health News:New Mesothelioma Treatment Shows Promise 2Health News:Honolulu, Hawaii Bariatric Surgery Practice Launches New Website to Reach Out to Patients Fighting Morbid Obesity 2Health News:Honolulu, Hawaii Bariatric Surgery Practice Launches New Website to Reach Out to Patients Fighting Morbid Obesity 3
... A fixed pipette is ... a single volume. Fixed volume ... and advantages as other Finnpipette ... design, Super blow-out (1-40ul), Soft-touch ...
Inquire...
... is precision, ergonomics, and value!, ... with soft non-slip, contoured handle , ... light plunger spring action , Completely ... without the need for recalibration , ...
100L...
Medicine Products: